BeOne Medicines (BEIGF) Long-Term Deferred Tax (2016 - 2023)

BeOne Medicines (BEIGF) has 8 years of Long-Term Deferred Tax data on file, last reported at $2.0 billion in Q4 2023.

• Long-Term Deferred Tax for Q4 2023 came in at $2.0 billion, down 2.38% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.0 billion (down 2.38% YoY), and the FY2023 annual result was $2.0 billion, down 2.38% from the prior year.
• Long-Term Deferred Tax fell to $2.0 billion in Q4 2023 per BEIGF's latest filing, from $2.1 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $2.1 billion in Q4 2022 and troughed at $30.5 million in Q1 2019.
• A 5-year average of $328.5 million and a median of $66.0 million in 2020 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2019 and 2023: Long-Term Deferred Tax surged 155.83% in 2019, then fell 2.38% in 2023.
• A 5-year view of Long-Term Deferred Tax shows it stood at $37.9 million in 2019, then jumped by 74.07% to $66.0 million in 2020, then jumped by 61.98% to $106.8 million in 2021, then jumped by 1846.59% to $2.1 billion in 2022, then decreased by 2.38% to $2.0 billion in 2023.
• Business Quant data shows BEIGF's Long-Term Deferred Tax at $2.0 billion in Q4 2023, $2.1 billion in Q4 2022, and $103.4 million in Q2 2022.